SARCOTHAL. Thalidomide in Skin Sarcoidosis

• Status: Completed
• Trial end date: 2007-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Sarcoidosis is a multisystem disease involving most frequently the lung, the eyes, the lymph nodes and the skin. Skin lesions may be disfiguring and impair the quality of life. Thalidomide is a multi-target drug that has been shown to be of benefit in skin sarcoidosis in case reports. The objective is to assess the efficacy and tolerance of thalidomide in skin sarcoidosis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assistance Publique - Hôpitaux de Paris
• Treatments: Thalidomide

Criteria

Inclusion Criteria:

• Biopsy proven skin sarcoidosis

• Assessable target skin lesions

Exclusion Criteria:

• Rapidly evolving sarcoidosis

• Patients necessitating a corticosteroid regimen of more than 15mg per day.

• Women not willing to undertake a contraceptive method.

• Neurologic impairment

• Past treatment with Thalidomide

• Renal impairment